Nearly $1B couldn't build a US glove industry
Supply Chain Pulse — 2026-07-11
Nearly $1 billion in federal investment failed to establish a sustainable domestic medical glove manufacturing sector — and hospitals are still as import-dependent as they were during the COVID-19 shortages. That sobering reality lands the same week Otsuka ICU Medical commits $500 million to expand U.S. IV and infusion device production in Texas, a reminder that reshoring success is highly uneven across product categories. Together, the two stories frame a core tension supply chain leaders will be navigating for years: which domestic manufacturing bets actually hold, and which are money pits. If gloves couldn't make it work with nearly a billion dollars behind them, scrutinize any reshoring narrative that doesn't include a credible cost-competitiveness path.
Almost $1B later, the US still can't make a medical glove
Despite nearly $1 billion in federal pandemic-era support, no durable domestic medical glove industry took root — leaving hospitals just as exposed to import disruptions today as they were in 2020. The failure stems from an inability to compete on unit cost with entrenched Southeast Asian manufacturers, even with subsidies factored in. For supply chain teams banking on domestic sourcing as a risk-mitigation strategy, gloves remain a category where diversifying your import base — not eliminating it — is the realistic hedge.
Otsuka ICU Medical outlays $500M to expand US manufacturing footprint
Otsuka ICU Medical is committing $500 million to build a new U.S. manufacturing facility and upgrade its existing Austin, Texas site, targeting IV solutions and infusion therapy products — categories that faced critical shortages as recently as 2023. The investment signals continued private-sector confidence in domestic production for high-acuity, clinically critical supplies where hospitals have demonstrated willingness to pay a premium for supply security. For IDNs and ASCs still managing IV fluid allocation protocols, this capacity expansion is worth tracking as a medium-term buffer against future disruption.
Source: Medical Device Network
How states are filling the 340B policy vacuum
With federal 340B oversight stalled, states are moving aggressively to set their own rules on contract pharmacy access, PBM reimbursement practices, and program transparency requirements — creating a patchwork of compliance obligations for covered entities operating across state lines. For health system pharmacy and supply chain teams, this means 340B program management is becoming an increasingly state-specific exercise, not a single federal framework. Covered entities should be auditing their contract pharmacy arrangements against the regulatory posture of each state where they operate.
Hospitals keep hiring, but nonclinical jobs face cuts
Healthcare employers continue adding clinical headcount while quietly trimming administrative and support roles — a bifurcation that is beginning to reach supply chain, materials management, and procurement departments at some systems. For supply chain leaders, the trend signals mounting pressure to demonstrate ROI through technology adoption and process efficiency rather than headcount growth. If your team hasn't made a clear case for the cost savings it drives, now is the time to build that narrative before the next budget cycle.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe